

AUSTRALIA BIOTECH INVEST 2013

Investor Highlights:

- Established in 1975 as a contract drug development company, \$10.2m revenues in 2012
- API, finished dose form and clinical capabilities
- Facilities, experience and regulatory packages have set the platform for a rapid move into generic oncology drug registrations



IDT AUSTRALIA LIMITED (IDT:ASX)

28 October 2013 – Melbourne

New Management Team: Driving Growth and Value

A. Organic business growth and a return to profitability through better sales and marketing, and efficiencies

B. Previously underleveraged off balance sheet assets: DMFs and generic oncology registrations

C. Transformational high value assets accelerated by IDT capabilities and skills: pro-drugs and super-generics



Japanese pharma opportunities via new shareholder from

innovation containment compliance

Melbourne Manufacturing Campus

12,000m² freehold site

\$70m+ replacement value, \$10m unimproved land value

1. Engineering
2. Warehouses/
inward goods
3. Cytotoxic labs
4. Dev. labs
5. Administration
6. Controlled store
7. Antibiotic API/FP
8. HPAPI + sterile
9. Utilities
10. Oral dose forms



innovation containment compliance

Melbourne Site Virtual Tour




CMAX: Royal Adelaide Hospital

- 445 studies completed over 20yrs
- Australia's largest clinical trial unit
- More patients safely and successfully dosed than any other facility
- Access to healthy volunteers and clinical patients



innovation containment compliance


30 Years Experience in Dangerous and Difficult to Manufacture Drugs



innovation containment compliance

Amended New Drug Application (ANDA)

- Process for registering a generic drug in the US




Simple
Registration
Process

Generic
Oncology
Portfolio

Moving up the Value Chain

- Case Study, Drug X:
 - IDT currently the dominant supplier of API into a large market, yet capturing a less than 1% as an API supplier
 - Registration and supply of Finished Dose Form could increase IDT's share of value chain to approximately 50%
- There are a number of these assets within IDT that have not been leveraged



- API (\$m)
- FDF (\$m)
- Marketer (\$m)



innovation containment compliance



Corporate Snapshot (as at 23Oct13)

Financials

	<u>2012</u>	<u>2013</u>
Rev	\$9.9m	\$10.6m
EBIT	(\$3.6)	(\$4.4)
Cash use	(\$1.4)	(\$2.2)
Debt	\$1.95m	

Register

- 75.56 m shares on issue
- 500,000 options (unlisted)
- Top 20 holders 61.5% (22Oct13)




innovation containment compliance

Summary

- \$70M+ purpose-built drug manufacturing and development facility, ample capacity for growth
- Australia's largest and only private clinical trials unit
- Reliable base revenues from drug development, drug manufacture, clinical trials
- 30 year history has resulted in the ownership of multiple Drug Master Files, now being converted to IDT generic drug registrations
- Capability and skills to acquire and grow value of larger, higher value projects such as reformulations or super-generics such as pro-drugs



innovation containment compliance



Paul D. R. MacLeman



Managing Director
+61 3 9801-8888
info@idtaus.com.au